Novel Drug Delivery Systems Market

North America Novel Drug Delivery Systems Market by Route of administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, and Others), Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, and Modulated Drug Delivery Systems), and Geography (US, Canada, and Mexico) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1496
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 183
  • Format:
  • Pub. Date: Upcoming
  • Share:

The North America novel drug delivery systems market size is anticipated to expand at a robust CAGR during the forecast period, 2021-2028. The growth of the market is attributed growing requirement for devices that confer controlled release of drugs. Moreover, the technological advancements promoting the development of NDDS is driving the market growth.

North America Novel Drug Delivery Systems Market Key Takeaways

Novel drug delivery system (NDDS) is a carrier that maintain the drug concentration in therapeutic range for longer period of time. This system refers to the approaches, formulations, and technologies used for transporting a pharmaceutical compound in the body safely to achieve its desired therapeutic effects.
Novel drugs are innovative products that serve previously unmet medical requirements or significantly helps to improve patient care and public health. New molecular entity (NME) drugs are expected to fuel the growth of the market. NDDS reduces the total amount of drug administered over the period of drug treatment.

Market Trends, Drivers, Restraints, and Opportunities:

  • Growing awareness about its benefits such as cost-effectiveness, least sterility constraints, and flexibility in the design of dosage form is expected to augment the North america novel drug delivery systems market growth.
  • Stringent regulatory guidelines can restraint the growth of the market.
  • Product recalls can be a serious issue for novel drug delivery system, which in turn, can hinder the market growth.
  • The COVID-19 outbreaks is expected to create lucrative opportunities for the growth of the market.

Scope of the Report

The report on the North america novel drug delivery systems market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

North America Novel Drug Delivery Systems Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Route of administration (Oral Drug Delivery Systems, Injectable Drug Delivery Systems, Pulmonary Drug Delivery Systems, Transdermal Drug Delivery Systems, Others), and Mode of NDDS (Targeted Drug Delivery Systems, Controlled Drug Delivery Systems, Modulated Drug Delivery Systems)

Geographical scope

US, Canada, and Mexico

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Roche Holding AG, Merck & Co., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi SA

 

North America Novel Drug Delivery Systems Market Segment Insights:

 Oral drug delivery systems segment to grow at a rapid pace

Based on route of administration, the market is divided into oral drug delivery systems, injectable drug delivery systems, pulmonary drug delivery systems, transdermal drug delivery systems, and others. The oral drug delivery systems segment is anticipated to account for a significant market share and is anticipated to grow at a rapid pace during the forecast period. Increasing incidence of chronic diseases, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by major pharmaceutical companies for the development of oral drug delivery technologies are expected to propel the segment growth.

Targeted drug delivery systems segment to account a major market share

On the basis of mode of NDDS, the market is segmented into targeted drug delivery systems, controlled drug delivery systems, modulated drug delivery systems. The targeted drug delivery systems segment is anticipated to account for a major market share in the projected timeline. Targeted drug delivery (TDD) is emerging as a powerful tool for the treatment of cancer owing to enhanced delivery of drugs, as well as genes, to a tumor site with protection from the extracellular environment.

North America Novel Drug Delivery Systems Market by mode of NDDS

The US to account a considerable market share

In terms of geography, the market is segregated into US, Canada, and Mexico. The US to account for a considerable market share owing to rising geriatric population and increasing healthcare expenditure. Moreover, growing adopting a sedentary lifestyle has led to incidence of diseases that require novel systems, as conventional drug delivery system cannot address the newer conditions and problems.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Novel Drug Delivery Systems Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Novel Drug Delivery Systems Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Novel Drug Delivery Systems Market - Supply Chain
  4.5. Global Novel Drug Delivery Systems Market Forecast
     4.5.1. Novel Drug Delivery Systems Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Novel Drug Delivery Systems Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Novel Drug Delivery Systems Market Absolute $ Opportunity
5. Global Novel Drug Delivery Systems Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Novel Drug Delivery Systems Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
6. North America Novel Drug Delivery Systems Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Novel Drug Delivery Systems Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
7. Latin America Novel Drug Delivery Systems Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Novel Drug Delivery Systems Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
8. Europe Novel Drug Delivery Systems Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Novel Drug Delivery Systems Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
9. Asia Pacific Novel Drug Delivery Systems Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Novel Drug Delivery Systems Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
10. Middle East & Africa Novel Drug Delivery Systems Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Novel Drug Delivery Systems Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Novel Drug Delivery Systems Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Novel Drug Delivery Systems Market: Market Share Analysis
  11.2. Novel Drug Delivery Systems Distributors and Customers
  11.3. Novel Drug Delivery Systems Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbott Laboratories
     11.4.2. Roche Holding AG
     11.4.3. Merck & Co.
     11.4.4. GlaxoSmithKline PLC
     11.4.5. Bayer AG
     11.4.6. AstraZeneca PLC
     11.4.7. F. Hoffmann-La Roche AG
     11.4.8. Johnson &

Segments Covered in the Report
The North America novel drug delivery systems have been segmented on the basis of

Route of administration

  • Oral Drug Delivery Systems
  • Injectable Drug Delivery Systems
  • Pulmonary Drug Delivery Systems
  • Transdermal Drug Delivery Systems
  • Others

Mode of NDDS

  • Targeted Drug Delivery Systems
  • Controlled Drug Delivery Systems
  • Modulated Drug Delivery Systems

Geography

  • United States
  • Canada
  • Mexico

Key Players

  • Abbott Laboratories
  • Roche Holding AG
  • Merck & Co.
  • GlaxoSmithKline PLC
  • Bayer AG
  • AstraZeneca PLC
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA.

The major players of the market are Abbott Laboratories, AstraZeneca PLC, Bayer AG, F. Hoffmann-La Roche AG, Roche Holding AG, Merck & Co., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi SA.

Companies are investing in research and development and focusing on development of innovative treatment options to expand their market share.

North America Novel Drug Delivery Systems Market by Key Players

Buy Report